SCHEMBL20103443

SCHEMBL20103443

COC(=O)[C@](C)(F)[C@H](c1cccc(O)c1)C1CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 5/20 0.44
OPRK1 P41145 4/20 0.43
OPRD1 P41143 3/20 0.43
SLC6A3 Q01959 2/20 0.35
SLC6A4 P31645 1/20 0.35
OPRM1 P35372 1/20 0.35
KDR P35968 1/20 0.35
ADRB2 P07550 1/20 0.35
ADRB1 P08588 1/20 0.35
HTR1A P08908 1/20 0.35
ADRA2A P08913 1/20 0.35
ADRB3 P13945 1/20 0.35
TSHR P16473 1/20 0.35
ADRA2B P18089 1/20 0.35
ADRA2C P18825 1/20 0.35
NFKB1 P19838 1/20 0.35
DRD1 P21728 1/20 0.35
HTR7 P34969 1/20 0.35
ADRA1A P35348 1/20 0.35
ADRA1B P35368 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20103527 1.00 FFAR1 (0.44) FFAR1OPRK1OPRD1SLC6A3SLC6A4
SCHEMBL20103446 1.00 FFAR1 (0.44) FFAR1OPRK1OPRD1SLC6A3SLC6A4
SCHEMBL29454623 0.89 OPRK1 (0.40) FFAR1OPRK1OPRD1SLC6A3SLC6A4
SCHEMBL22717576 0.89 OPRK1 (0.40) FFAR1OPRK1OPRD1SLC6A3SLC6A4
SCHEMBL22717578 0.89 OPRK1 (0.40) FFAR1OPRK1OPRD1SLC6A3SLC6A4
SCHEMBL25474456 0.89 OPRK1 (0.40) FFAR1OPRK1OPRD1SLC6A3SLC6A4
SCHEMBL22717575 0.89 OPRK1 (0.40) FFAR1OPRK1OPRD1SLC6A3SLC6A4
SCHEMBL21688395 0.86 FFAR1 (0.43) FFAR1OPRK1ADRB2ADRB1ADRB3
SCHEMBL20103672 0.86 FFAR1 (0.57) FFAR1POLB
SCHEMBL21644927 0.85 FFAR1 (0.48) FFAR1OPRK1OPRD1SLC6A3SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10988433-B2 Cyclohexyl GPR40 agonists for the treatment of type II diabetes JANSSEN PHARMACEUTICA NV (BE) 2021-04-27 US disclosed
US-20200039914-A1 CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES JANSSEN RESEARCH & DEVELOPMENT, LLC 2020-02-06 US disclosed
WO-2018081047-A1 CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES JANSSEN PHARMACEUTICA NV (BE) 2018-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200039914-A1 CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES GPR119, GPR65, GPR55 FFAR1 16/4885OPRK1 378/4885OPRD1 515/4885
US-10988433-B2 Cyclohexyl GPR40 agonists for the treatment of type II diabetes GPR119, GPR65, GPR55 FFAR1 16/4885OPRK1 378/4885OPRD1 515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.